MiR-502-3P suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting SET
Authors Jin H, Yu M, Lin Y, Hou B, Wu Z, Li Z, Sun J
Received 23 April 2015
Accepted for publication 19 October 2015
Published 31 May 2016 Volume 2016:9 Pages 3281—3289
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Nitin Kumar Agarwal
Peer reviewer comments 4
Editor who approved publication: Dr Faris Farassati
Haosheng Jin,* Min Yu,* Ye Lin, Baohua Hou, Zhongshi Wu, Zhide Li, Jian Sun
Department of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, People’s Republic of China
*These authors contributed equally to this work
Background/aim: Increasing evidences show that microRNAs are engaged in hepatocellular carcinoma (HCC). The aim of this study was to investigate the role of miR-502-3P in HCC and to identify its underlying mechanism.
Methods: The expression levels of miR-502-3P were assessed in multiple HCC cell lines and in liver tissues of patients with HCC. We further examined the effects of miR-502-3P on malignant behavior of HCC. The molecular target of miR-502-3P was identified using a computer algorithm and confirmed experimentally.
Results: Downregulation of miR-502-3P was found in both HCC cell lines and human samples. Overexpression of miR-502-3P dramatically inhibits HCC proliferation, metastasis, invasion, and cell adhesion. We further verify the SET as a novel and direct target of miR-502-3P in HCCs.
Conclusion: Taken together, overexpression of miR-502-3P or downregulation of SET may prove beneficial as a therapeutic strategy for HCC treatment.
Keywords: miRNA, HCC, SET gene, recurrence
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]